Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Substituted acylanilides and methods of use thereof

A technology for medicinal products and compounds, applied to substituted N-acyl anilides and their application fields, can solve the problems of increasing the risk of foot ulcers, complicating problems and the like

Inactive Publication Date: 2009-08-26
UNIV OF TENNESSEE RES FOUND
View PDF25 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, in diabetes, neuropathy increases the risk of foot ulcers, and its presence further complicates the problem
[0026] While there are many treatments and treatments for these conditions, none are ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted acylanilides and methods of use thereof
  • Substituted acylanilides and methods of use thereof
  • Substituted acylanilides and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0303] The preparation of pharmaceutical compositions comprising active ingredients is known in the art, for example by mixing, granulating or tabletting methods. The active therapeutic ingredient is usually mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. For oral administration, the compounds according to the invention or their physiologically tolerated derivatives such as salts, esters, N-oxides etc. are mixed with additives customary for this purpose such as carriers, stabilizers or inert diluents, and Conversion into a form suitable for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions, is carried out by conventional methods. For parenteral administration, the compounds of the present invention or their physiologically tolerated derivatives such as salts, esters, N-oxides, etc. are converted into solutions, suspensions or emulsions, if necessary, with c...

Embodiment 5

[0600] Example 5 demonstrates that the compounds of formula (I) have anabolic activity and minimal androgenic activity, and therefore these compounds can be used in the treatment of patient populations who were contraindicated in the past androgen. Compounds of formula (I) have been shown to stimulate muscle growth regardless of the presence or absence of testosterone and still exert an antiproliferative effect on the prostate, thus in one embodiment the methods of the invention restore muscle mass loss in sarcopenia or cachexia patients.

[0601] In one embodiment, the compounds described herein alter leptin levels in a subject. In another embodiment, the compounds described herein lower leptin levels. In another embodiment, the compounds described herein increase leptin levels in a subject. Leptin is known to have an effect on appetite in obese mice, resulting in weight loss, so it is associated with obesity.

[0602] In one embodiment, the compounds described herein affec...

Embodiment 1

[0683] Synthesis of the (S) enantiomer of the compound of formula (I) ( Figures 1A-1L )

[0684]

[0685] (2R)-1-methacryloylpyrrolidine-2-carboxylic acid. D-proline (14.93g, 0.13mol) was dissolved in 71mL of 2N NaOH and cooled in an ice bath; the resulting alkaline solution was washed with acetone (71mL )dilution. A solution of methacryloyl chloride (13.56 g, 0.13 mol) in acetone (71 mL) and 2N NaOH (71 mL) were added simultaneously to an aqueous D-proline solution in an ice bath over 40 min. During the addition of methacryloyl chloride, the pH of the mixture was maintained at 10-11°C. After stirring (3 h, room temperature), the mixture was evaporated in vacuo at a temperature of 35-45 °C to remove acetone. The resulting solution was washed with ether and acidified to pH 2 with concentrated HCl. The acidic mixture was saturated with NaCl and extracted with EtOAc (100 mL x 3). Combined extracts with Na 2 SO 4 Dry, filter through Celite, and evaporate in vacuo to g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to View More

Abstract

This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and / or disorder or a bone-related disease and / or disorder.

Description

technical field [0001] The present invention provides substituted anilide compounds and their use in the treatment of a variety of diseases or conditions in a subject, including in particular muscular wasting diseases and / or disorders or bone related diseases and / or disorders. Background technique [0002] The nuclear hormone receptor superfamily is one of the largest classes of transcription factors and is involved in many physiological processes. The 48 members of this family are divided into three classes, class 1 consists of androgens (AR), estrogens (ER-α and ER-β), glucocorticoids (GR), progesterone (PR) and mineralocorticoids (MR ) receptor composition. Class 2 includes receptors for retinoids, thyroid and vitamin D, while class 3 includes receptors for which ligands are still to be identified (orphan receptors). Nuclear hormone receptors contain: a functionally less characterized N-terminal domain (NTD), a DNA-binding domain (DBD) responsible for binding the recept...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C391/00C07C275/40
CPCC07C255/60A61P19/00A61P43/00A61K31/277A61P11/00A61P13/12A61P15/00A61P15/10A61P15/16A61P17/02A61P17/14A61P19/08A61P19/10A61P21/00A61P21/04A61P25/02A61P25/04A61P25/24A61P25/28A61P25/32A61P27/04A61P3/00A61P3/02A61P3/04A61P31/08A61P31/18A61P35/00A61P35/02A61P5/26A61P7/06A61P9/00A61P9/10A61P3/10C07C235/38A61K31/16
Inventor J·T·多尔顿D·D·米勒
Owner UNIV OF TENNESSEE RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com